World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
35853
World Ranking
8601
National Ranking
843

Overview

Peter Johnson is affiliated with the University of Southampton in the United Kingdom and has contributed extensively to the field of medicine, with a specialization in pathology and forensic medicine, oncology, pulmonary and respiratory medicine, genetics, and molecular biology. Their research output spans over 313 publications, emphasizing lymphoma diagnosis and treatment, lung cancer treatments and mutations, chronic lymphocytic leukemia research, CAR-T cell therapy research, as well as COVID-19 related healthcare and clinical research studies.

Notable recent publications by Johnson include:

  • "Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study" (2020, BMJ)
  • "Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study" (2021, BMJ)
  • "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" (2020, Annals of Oncology)
  • "Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study" (2021, The Lancet)
  • "Discovering dominant tumor immune archetypes in a pan-cancer census" (2021, Cell)

Frequent co-authors collaborating with Johnson, reflecting repeated partnerships in research, are:

  • Andrew Davies
  • Emanuele Zucca
  • John Radford
  • Sally F. Barrington
  • David Hodgson

Johnson's publications frequently appear in the following venues, which indicate their primary outlets for disseminating research findings:

  • Blood
  • Hematological Oncology
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood Advances

In addition to journal articles, Johnson has contributed to book publications, including a title under Bloomsbury Academic eBooks titled "R. G. Collingwood and the Second World War" published in 2020.

The overarching topics of Johnson's work center on:

  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • COVID-19 and healthcare impacts
  • COVID-19 Clinical Research Studies

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Michael L. Wang;Simon Rule;Peter Martin;Andre Goy

  • Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

    B. Coiffier;C. Haioun;N. Ketterer;A. Engert

  • Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    H Tilly;M Gomes da Silva;U Vitolo;A Jack

  • Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

    Peter Johnson;Massimo Federico;Amy A Kirkwood;Alexander Fossa

  • Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

    John Radford;Tim Illidge;Nicholas Counsell;Barry Hancock

  • European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

    James M. Foran;Ama Z. S. Rohatiner;David Cunningham;Razvan A. Popescu

  • Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

    Mark S Cragg;Suzanne M Morgan;H T Claude Chan;B Paul Morgan

  • Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

    David Cunningham;Eliza A Hawkes;Andrew Jack;Wendi Qian

  • Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

    Andrés J M Ferreri;Kate Cwynarski;Elisa Pulczynski;Maurilio Ponzoni

  • Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    Anas Younes;Laurie H. Sehn;Peter Johnson;Pier Luigi Zinzani

  • Clinical trials of antibody therapy.

    Martin J Glennie;Peter W.M Johnson

  • Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

    Michael L. Wang;Kristie A. Blum;Peter Martin;Andre Goy

  • Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.

    P. W. M. Johnson;A. Z. S. Rohatiner;J. S. Whelan;C. G. A. Price

  • Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

    Stephen A. Beers;Ruth R. French;H. T. Claude Chan;Sean H. Lim

  • Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

    Sally F. Barrington;Wendi Qian;Edward J. Somer;Antonella Franceschetto

  • Autocrine Production of Interleukin 6 Causes Multidrug Resistance in Breast Cancer Cells

    Dietrich Conze;Linda Weiss;Patricia Susan Regen;Alok Bhushan

  • Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    Andres J. M. Ferreri;Kate Cwynarski;Elisa Pulczynski;Christopher P. Fox

  • Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling

    Ferdousi Chowdhury;Anthony Williams;Peter Johnson

  • First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

    Anton Hagenbeek;Ole Vestergaard Gadeberg;Peter Johnson;Lars Møller Pedersen

  • The mechanisms of action of rituximab in the elimination of tumor cells

    Peter W M Johnson;Martin J Glennie

Frequent Co-Authors

John Radford
John Radford University of Manchester
Martin J. Glennie
Martin J. Glennie University of Southampton
Graham Packham
Graham Packham University of Southampton
Mark S. Cragg
Mark S. Cragg University of Southampton
Emanuele Zucca
Emanuele Zucca Universita della Svizzera Italiana
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Freda K. Stevenson
Freda K. Stevenson University of Southampton
Peter Selby
Peter Selby University of Leeds
David C. Linch
David C. Linch University College London
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring healthcare careers goes beyond traditional medicine. Many students combine flexibility with career growth by pursuing online degrees in related fields. For those already working as registered nurses, cost is a significant consideration—see an in-depth guide to rn to bsn online cost to help plan your budget.

Individuals without prior nursing backgrounds looking to enter the field quickly may consider direct entry online msn programs. These programs are designed for career changers and can streamline your pathway to advanced nursing degrees.

Admission can also be a concern. If you’re looking for accessible options, some recommend exploring nursing programs with high acceptance rates, helping you find institutions with less stringent entry requirements.

Beyond nursing, medical billing and coding is another in-demand healthcare career accessible online. Learn about medical billing and coding online schools that accept financial aid, making it more affordable to start this vital administrative role.

Best Scientists Citing Peter Johnson

Trending Scientists

Recently Published Articles